Biomedical Bonding AB is a biotechnology company based in Stockholm that specializes in biomedical bonding and medical adhesives. The company focuses on developing products for bone and dental restoration, aiming to minimize recovery time and reduce postsurgical complications. Their product offerings include fracture implants designed for both humans and animals, highlighting their commitment to advancing medical technology across species.
The company is actively engaged in pre-clinical implantation studies and collaborates with various institutions, including RISE, SÖS, and CCMIJU. Biomedical Bonding AB has also contributed to the academic community by publishing research on their product AdhFix in the journal Frontiers in Bioengineering and Biotechnology. Their comparative analysis of Bonevolent™-AdhFix versus traditional metal plates underscores their innovative approach to fracture treatment technology.
Leadership at Biomedical Bonding AB includes a Chief Medical Officer and a Chief Operating Officer, reflecting a structured management team dedicated to the company's mission. Through their research and development efforts, the company aims to enhance the effectiveness of fracture treatment and contribute to advancements in the field of biomedical engineering.